Ŭ¶ó¹Ìµð¾Æ ½ÃÀå - ¼¼°è ¹× Áö¿ªº° ºÐ¼® : À¯Åë ä³Îº°, Áö¿ªº°, ±¹°¡º° - ºÐ¼®°ú ¿¹Ãø(2025-2035³â)
Chlamydia Market - A Global and Regional Analysis: Focus on Distribution Channel, Country, and Region - Analysis and Forecast, 2025-2035
»óǰÄÚµå : 1753877
¸®¼­Ä¡»ç : BIS Research Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,900 £Ü 6,698,000
PDF and Excel (1-3 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,253,000
PDF and Excel (Global License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ŭ¶ó¹Ìµð¾Æ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â Àü ¼¼°è Ŭ¶ó¹Ìµð¾Æ °¨¿°·üÀÇ Áõ°¡ÀÔ´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)´Â ¸Å³â ¾à 1¾ï 2,700¸¸ ¸íÀÇ ½Å±Ô °¨¿°ÀÚ°¡ º¸°íµÇ°í ÀÖÀ¸¸ç, ƯÈ÷ ÀþÀº ¼ºÀÎÀÇ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ º¸´Ù È¿°úÀûÀÎ Áø´Ü ¹× Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °¨¿°ÁõÀÇ ±ÞÁõÀº ½Å¼ÓÇÑ Áø´Ü°ú Àû½Ã Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â °í°¨µµ ÇÙ»ê ÁõÆø°Ë»ç(NAAT) ¹× ½Å¼Ó ÇöÀåÁø´Ü °Ë»ç(POCT)¿Í °°Àº ÷´Ü °Ë»ç ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °øÁߺ¸°Ç ³ë·Â°ú °ËÁø ÇÁ·Î±×·¥ÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÎ½Ä °³¼±°ú °Ë»ç Àå·Á¸¦ ÅëÇØ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ Á¾ÇÕÀûÀ¸·Î Ŭ¶ó¹Ìµð¾Æ ½ÃÀåÀÇ ¿ªµ¿ÀûÀÎ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÇ·á ½Ã½ºÅÛÀÌ ÀÌ ³Î¸® ÆÛÁø ¼ºº´À» ´õ Àß °ü¸®Çϰí ÅëÁ¦Çϱâ À§ÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù.

ÇÑÆí, ½ÃÀå ¼ºÀå¿¡µµ ºÒ±¸Çϰí, ¸î °¡Áö ¹®Á¦µéÀÌ ±× ÀáÀç·ÂÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù. °¡Àå Å« °É¸²µ¹Àº Ŭ¶ó¹Ìµð¾Æ °¨¿°ÀÇ ¹«Áõ»ó¼ºÀε¥, ƯÈ÷ ¿©¼ºÀÇ °æ¿ì 70-80%°¡ Áø´ÜµÇÁö ¾Ê¾Æ Àû½Ã¿¡ ¹ß°ßÇϰí Ä¡·áÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ºº´¿¡ ´ëÇÑ »çȸÀû Æí°ß°ú ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ¸¹Àº »ç¶÷µéÀÌ °Ë»ç ¹× Ä¡·á¸¦ ¹Þ´Â °ÍÀ» ÁÖÀúÇϰí ÀÖ½À´Ï´Ù. ÁßÀú¼Òµæ ±¹°¡¿¡¼­´Â ºñ¿ë°ú ÀÎÇÁ¶óÀÇ Á¦¾àÀ¸·Î ÀÎÇØ Àú·ÅÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ¿©ÀüÈ÷ Á¦ÇѵǾî ÀÖ¾î °ËÁø º¸±Þ¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç×»ýÁ¦ ³»¼ºÀÇ À§Çùµµ ½É°¢ÇÑ ¹®Á¦À̸ç, Ç×»ýÁ¦ÀÇ ¿À³²¿ë°ú °ú´Ù »ç¿ëÀº Ä¡·á È¿°ú¸¦ ¶³¾î¶ß¸± ¼ö ÀÖ½À´Ï´Ù. ÀϺΠÁö¿ªÀÇ ±ÔÁ¦ À庮°ú ´ÜÆíÀûÀÎ ÀÇ·á ½Ã½ºÅÛµµ »õ·Î¿î Áø´Ü ±â¼úÀÇ Ã¤ÅÃÀ» ´ÊÃß°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦µéÀ» ÇØ°áÇÏ´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» Áö¼ÓÇÏ°í ¼¼°è ¼º °Ç°­ ¼º°ú¸¦ °³¼±ÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¼¼°è Ŭ¶ó¹Ìµð¾Æ ½ÃÀå¿¡¼­´Â Ä¡·áÀÇ ¹Ì·¡¸¦ Å©°Ô Á¿ìÇÒ ¸î °¡Áö Áß¿äÇÑ ½ÅÈï Æ®·»µå°¡ ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù. °¡Àå ´«¿¡ ¶ç´Â °ÍÀº ÇöÀå °Ë»ç(POCT) ±â¼úÀÇ ±Þ¼ÓÇÑ µµÀÔÀÔ´Ï´Ù. ÀÌ ±â¼úÀº ȯÀÚ°¡ ÀÖ´Â °÷¿¡¼­ °ÅÀÇ Áï°¢ÀûÀÎ Áø´Ü°ú Ä¡·á °áÁ¤À» ³»¸± ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â Áø´Ü Áö¿¬À» ÁÙÀ̰í, ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀ̸ç, ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ª°ú ¿ø°ÝÁö¿¡¼­ °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇØ¾ß ÇÒ Çʿ伺¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Ŭ¶ó¹Ìµð¾Æ, ÀÓÁú, Æ®¸®Äڸ𳪽ºÁõ µî ¿©·¯ ¼ºº´À» µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º °Ë»ç Ç÷§ÆûÀÇ ÅëÇÕÀÌ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, Áø´ÜÀÇ È¿À²¼º°ú ÀÓ»óÀû ÆÇ´ÜÀÇ Áú Çâ»ó¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ Æ®·»µå´Â Ç×±ÕÁ¦ÀÇ ¿Ã¹Ù¸¥ »ç¿ë°ú ³»¼º ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ´Â Ç×»ýÁ¦ ³»¼º Áõ°¡·Î ÀÎÇØ ÇöÀçÀÇ Ä¡·á ¿ä¹ý¿¡ ¾î·Á¿òÀ» °Þ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý °Ë»ç, ¿Â¶óÀÎ Áø·á, ÈÄ¼Ó Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â µðÁöÅÐ °Ç°­ µµ±¸ ¹× ¿ø°ÝÀÇ·áÀÇ À̿뵵 Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ´õ ¸¹Àº »ç¶÷µé¿¡°Ô Á¢±Ù¼ºÀ» ³ÐÈ÷°í ȯÀÚÀÇ ÇÁ¶óÀ̹ö½Ã¸¦ Çâ»ó½ÃŰ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµç Ãß¼¼´Â º¸´Ù ȯÀÚ Áß½ÉÀûÀÌ°í ±â¼ú ÁÖµµÀûÀÎ Á¢±Ù ¹æ½ÄÀ» ¹Ý¿µÇϰí ÀÖÀ¸¸ç, Ä¡·á °á°ú¸¦ °³¼±Çϰí Àü ¼¼°èÀûÀÎ °¨¿° È®»êÀ» ¾ïÁ¦ÇÏ´Â µ¥ ±â¿©ÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¼¼°èÀÇ Å¬¶ó¹Ìµð¾Æ ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ÁÖ¿ä µ¿Çâ, ½ÃÀå ¿µÇâ¿äÀÎ ºÐ¼®, ¹ý¡¤±ÔÁ¦ ȯ°æ, ÀÓ»ó½ÃÇè µ¿Çâ, ½ÃÀå ±Ô¸ð ÃßÁ¤ ¹× ¿¹Ãø, °¢Á¾ ºÎ¹®º°¡¤Áö¿ªº°¡¤ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå ¼¼°èÀÇ Å¬¶ó¹Ìµð¾Æ ½ÃÀå : ¾÷°è Àü¸Á

Á¦2Àå ¼¼°èÀÇ Å¬¶ó¹Ìµð¾Æ ½ÃÀå : À¯Åë ä³Îº°

Á¦3Àå ¼¼°èÀÇ Å¬¶ó¹Ìµð¾Æ ½ÃÀå : Áö¿ªº°

Á¦4Àå ¼¼°èÀÇ Å¬¶ó¹Ìµð¾Æ ½ÃÀå : °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦5Àå Á¶»ç ¹æ¹ý

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Chlamydia Market, Analysis and Forecast: 2025-2035

Chlamydia is a common sexually transmitted infection (STI) caused by the bacterium Chlamydia trachomatis. It often presents without noticeable symptoms, especially in women, which can lead to undiagnosed and untreated infections. If left untreated, chlamydia can cause serious health complications such as pelvic inflammatory disease (PID), infertility, ectopic pregnancy, and increased susceptibility to other infections, including HIV. Because of its high prevalence estimated at around 127 million new cases globally each year chlamydia represents a significant public health challenge, necessitating effective screening, timely diagnosis, and treatment to control its spread.

One of the key drivers of the chlamydia market is the rising prevalence of chlamydia infections worldwide. With approximately 127 million new cases reported annually by the World Health Organization, the increasing incidence particularly among young adults has created a pressing need for more effective diagnostic and therapeutic solutions. This surge in infections drives demand for advanced testing technologies, such as highly sensitive Nucleic Acid Amplification Tests (NAATs) and rapid Point-of-Care Testing (POCT), which enable quicker diagnosis and timely treatment. Additionally, public health initiatives and screening programs are expanding, further boosting market growth by increasing awareness and encouraging testing. Collectively, these factors contribute to the dynamic expansion of the chlamydia market as healthcare systems strive to better manage and control this widespread sexually transmitted infection.

Despite the growth of the chlamydia market, several challenges continue to impede its full potential. A major obstacle is the asymptomatic nature of chlamydia infections, with up to 70-80% of cases going undiagnosed, especially among women, which hinders timely detection and treatment. Additionally, social stigma and privacy concerns around sexually transmitted infections discourage many individuals from seeking testing and care. Access to affordable and reliable diagnostic tools remains limited in low- and middle-income countries due to cost and infrastructure constraints, restricting widespread screening efforts. Furthermore, the looming threat of antibiotic resistance poses a significant challenge, as misuse or overuse of antibiotics can reduce treatment effectiveness. Regulatory hurdles and fragmented healthcare systems in some regions also delay the adoption of new diagnostic technologies. Addressing these challenges is critical to sustaining market growth and improving global sexual health outcomes.

The global chlamydia market is highly competitive, characterized by the presence of several key players driving innovation in diagnostics and therapeutics. Companies such as ActivBiotics Pharma LLC, Bausch Health (Endo Pharmaceuticals), and Allergan (Warner Chilcott) are notable for their extensive product portfolios targeting chlamydia treatment and management. Diagnostic leaders like Hologic (Gen-Probe Incorporated) and Meridian Bioscience Inc. focus on advancing rapid and accurate testing technologies, including nucleic acid amplification tests (NAATs) and point-of-care platforms. Additionally, Evofem Inc. and Clinical Research Management Inc. (CRMI) contribute through clinical research and novel therapeutic approaches. Pharmaceutical giants Pfizer Inc. and Merck KGaA further bolster the market with a broad range of antibiotics and treatment options. The competitive intensity among these players is fuelled by continuous investment in research and development, strategic collaborations, and efforts to expand access to innovative diagnostics and therapeutics globally. This dynamic ecosystem promotes rapid advancements aimed at improving detection, treatment efficacy, and patient outcomes in the fight against chlamydia infections.

Market Segmentation:

Segmentation 1: by Distribution Channel

Segmentation 2: by Region

The global chlamydia market is experiencing several key emerging trends that are significantly shaping the future of treatment. One of the most prominent trends is the rapid adoption of Point-of-Care Testing (POCT) technologies, which enable near-instantaneous diagnosis and treatment decisions at the patient's location. This shift is driven by the need to reduce diagnostic delays, improve patient compliance, and expand access to testing in resource-limited and remote settings.

Additionally, integration of multiplex testing platforms that simultaneously detect multiple sexually transmitted infections including chlamydia, gonorrhea, and trichomoniasis is gaining momentum, streamlining diagnosis and enhancing clinical decision-making. Another critical trend is the growing emphasis on antimicrobial stewardship and resistance monitoring, as rising antibiotic resistance poses challenges to current treatment regimens. Furthermore, the market is witnessing increased use of digital health tools and telemedicine, which facilitate remote testing, consultation, and follow-up care, broadening outreach and improving privacy for patients. Together, these trends reflect a more patient-centric, technology-driven approach to chlamydia management that promises to improve outcomes and curb transmission rates worldwide.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Chlamydia Market: Industry Outlook

2. Global Chlamydia Market (Distribution Channel), ($Million), 2023-2035

3. Global Chlamydia Market (Region), ($Million), 2023-2035

4. Global Chlamydia Market: Competitive Landscape and Company Profiles

5. Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â